Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.42 |
| ▸ | ABAT | P80404 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660556 | 0.89 | KIF11 (0.40) | ALDH1A1TSHRKDM4ECYP1A2CYP3A4 | |
| SCHEMBL668308 | 0.85 | TUBB4A (0.48) | ALDH1A1TSHRKDM4ECYP1A2CYP3A4 | |
| SCHEMBL31128571 | 0.83 | ALDH1A1 (0.46) | ALDH1A1TSHRKDM4ECYP1A2CYP3A4 | |
| SCHEMBL16077415 | 0.83 | SRC (0.45) | ALDH1A1TSHRKDM4ECYP1A2CYP3A4 | |
| SCHEMBL1458171 | 0.81 | ALDH1A1 (0.49) | ALDH1A1TSHRCYP1A2CYP3A4HPGD | |
| SCHEMBL16610370 | 0.81 | ALDH1A1 (0.45) | ALDH1A1KDM4ECYP1A2CYP3A4CYP2C19 | |
| SCHEMBL16619850 | 0.81 | ALDH1A1 (0.59) | ALDH1A1TSHRKDM4ECYP1A2CYP3A4 | |
| SCHEMBL96635 | 0.81 | ALDH1A1 (0.59) | ALDH1A1TSHRKDM4ECYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL23711567 | 0.79 | ALDH1A1 (0.57) | ALDH1A1TSHRKDM4ECYP1A2HPGD | |
| SCHEMBL14835727 | 0.79 | PDCD1 (0.46) | ALDH1A1TSHRKDM4ECYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111902386-A | Phenyl methanone derivatives as FTO inhibitors | 瑞璞鑫(苏州)生物科技有限公司 | 2020-11-06 | — | — | CN | disclosed |
| US-10342766-B2 | 6-shogaol derivatives and activities thereof | NORTH CAROLINA AGRICULTURAL AND TECHNICAL STATE UNIVERSITY (US) | 2019-07-09 | — | — | US | disclosed |
| US-10188659-B2 | IGF-1R signaling pathway inhibitors useful in the treatment of neurodegenerative diseases | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2019-01-29 | — | — | US | disclosed |
| EP-3021944-B1 | IGF-1R SIGNALING PATHWAY INHIBITORS USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2018-12-19 | — | — | EP | disclosed |
| US-20180064725-A1 | IGF-1R SIGNALING PATHWAY INHIBITORS USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2018-03-08 | — | — | US | disclosed |
| US-9770454-B2 | IGF-1R signaling pathway inhibitors useful in the treatment of neurodegenerative diseases | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2017-09-26 | — | — | US | disclosed |
| US-20160158243-A1 | IGF-1R SIGNALING PATHWAY INHIBITORS USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2016-06-09 | — | — | US | disclosed |
| EP-3021944-A1 | IGF-1R SIGNALING PATHWAY INHIBITORS USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. (IL) | 2016-05-25 | — | — | EP | disclosed |
| EP-2658847-B1 | 2-(2-PHENYLETHENYL)-1,3-BENZOTHIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | YISSUM RES DEV CO (IL) | 2015-12-23 | — | — | EP | disclosed |
| US-9073880-B2 | 2-(2-phenylethenyl) 1,3-benzodiazepine derivatives useful for the treatment of cancer | Yissum Research Development Company of the Hebrew University of Jeruselem Ltd. (IL) | 2015-07-07 | — | — | US | disclosed |
| EP-2125712-B1 | NOVEL PROTEIN KINASE MODULATORS AND THERAPEUTIC USES THEREOF | NOVOTYR THERAPEUTICS LTD (IL) | 2014-07-23 | — | — | EP | disclosed |
| EP-2658847-A1 | 2 - (2 - PHENYLETHENYL) - 1, 3 -BENZOTHIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | Novotyr Therapeutics Ltd. (IL) | 2013-11-06 | — | — | EP | disclosed |
| US-20130274251-A1 | 2-(2-PHENYLETHENYL) 1,3-BENZODIAZEPINE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER | NOVOTYR THERAPEUTICS LTD. (IL) | 2013-10-17 | — | — | US | disclosed |
| WO-2012090204-A1 | 2 - (2 - PHENYLETHENYL) - 1, 3 -BENZOTHIAZINE DERIVATIVES USEFUL FOR THE TREATMENT CANCER | NOVOTYR THERAPEUTICS LTD. (IL) | 2012-07-05 | — | — | WO | disclosed |
| US-20120083528-A1 | NOVEL PROTEIN KINASE MODULATORS AND THERAPEUTIC USES THEREOF | NOVOTYR THERAPEUTICS LTD. (IL) | 2012-04-05 | — | — | US | disclosed |
| US-8058309-B2 | Protein kinase modulators and therapeutic uses thereof | NOVOTYR THERAPEUTICS LTD. (IL) | 2011-11-15 | — | — | US | disclosed |
| US-20100056635-A1 | NOVEL PROTEIN KINASE MODULATORS AND THERAPEUTIC USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2010-03-04 | — | — | US | disclosed |
| CN-101652345-A | Novel protein kinase modulators and its treatment are used | NOVOTYR THERAPEUTICS LTD IL | 2010-02-17 | — | — | CN | disclosed |
| EP-2125712-A1 | NOVEL PROTEIN KINASE MODULATORS AND THERAPEUTIC USES THEREOF | Novotyr Therapeutics Ltd. (IL) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008068751-A1 | NOVEL PROTEIN KINASE MODULATORS AND THERAPEUTIC USES THEREOF | NOVOTYR THERAPEUTICS LTD. (IL) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083528-A1 | NOVEL PROTEIN KINASE MODULATORS AND THERAPEUTIC USES THEREOF | PTK2B, LTK, MAP3K20 | ALDH1A1 4568/4885TSHR 974/4885KDM4E 1972/4885 |
| US-10188659-B2 | IGF-1R signaling pathway inhibitors useful in the treatment of neurodegenerative diseases | IGF1R, IRS1, IGFBP1 | ALDH1A1 4179/4885TSHR 945/4885KDM4E 4123/4885 |
| US-20180064725-A1 | IGF-1R SIGNALING PATHWAY INHIBITORS USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | IGF1R, IRS1, IGFBP1 | ALDH1A1 4179/4885TSHR 945/4885KDM4E 4123/4885 |
| US-20100056635-A1 | NOVEL PROTEIN KINASE MODULATORS AND THERAPEUTIC USES THEREOF | PTK2B, LTK, FRK | ALDH1A1 4531/4885TSHR 1178/4885KDM4E 1830/4885 |
| US-20130274251-A1 | 2-(2-PHENYLETHENYL) 1,3-BENZODIAZEPINE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER | GRK3, OPRK1, PKN3 | ALDH1A1 1787/4885TSHR 660/4885KDM4E 2134/4885 |
| US-10342766-B2 | 6-shogaol derivatives and activities thereof | NFE2L2, HMOX1, KEAP1 | ALDH1A1 844/4885TSHR 4271/4885KDM4E 4445/4885 |
| US-20160158243-A1 | IGF-1R SIGNALING PATHWAY INHIBITORS USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | IGF1R, IRS1, IGFBP1 | ALDH1A1 4179/4885TSHR 945/4885KDM4E 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.